Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies

Localized RNAi Therapeutics of Chemoresistant Grade IV Glioma Using Hyaluronan-Grafted Lipid-Based Nanoparticles

(2015) Zvi R. Cohen et al.   ACS Nano

Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles

(2015) Srinivas Ramishetti et al.   ACS Nano

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

(2015) C. Y. Cheah et al.   ANNALS OF ONCOLOGY

CD38 Monoclonal Antibody Therapies for Multiple Myeloma

(2015) Sandy W. Wong et al.   Clinical Lymphoma Myeloma & Leukemia

Knocking down disease: a progress report on siRNA therapeutics

(2015) Anders Wittrup et al.   NATURE REVIEWS GENETICS

Mantle cell lymphoma: evolving management strategies

(2014) Elias Campo et al.   BLOOD

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting

(2014) T Vaisitti et al.   LEUKEMIA

Non-viral vectors for gene-based therapy

(2014) Hao Yin et al.   NATURE REVIEWS GENETICS

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

(2013) B. Y. Chang et al.   BLOOD

A daunting task: manipulating leukocyte function with RNAi

(2013) Dan Peer   IMMUNOLOGICAL REVIEWS

Phase I First-in-Humans Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC)

(2013) Tracy Zimmermann et al.   JOURNAL OF CARDIAC FAILURE

Discovery of siRNA Lipid Nanoparticles to Transfect Suspension Leukemia Cells and Provide In Vivo Delivery Capability

(2013) Wei He et al.   MOLECULAR THERAPY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advances in Lipid Nanoparticles for siRNA Delivery

(2013) Yuen Tam et al.   Pharmaceutics

Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo

(2012) Muthusamy Jayaraman et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Molecular pathogenesis of mantle cell lymphoma

(2012) Pedro Jares et al.   JOURNAL OF CLINICAL INVESTIGATION

RNA Inhibition Highlights Cyclin D1 as a Potential Therapeutic Target for Mantle Cell Lymphoma

(2012) Shiri Weinstein et al.   PLoS One

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells

(2012) Tatiana I Novobrantseva et al.   Molecular Therapy-Nucleic Acids

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

(2012) Nathan M Belliveau et al.   Molecular Therapy-Nucleic Acids

Special delivery: targeted therapy with small RNAs

(2011) D Peer et al.   GENE THERAPY

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

(2010) P. Perez-Galan et al.   BLOOD

RNAi nanomedicines: challenges and opportunities within the immune system

(2010) Shiri Weinstein et al.   NANOTECHNOLOGY

The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies

(2009) G. Tchakarska et al.   HAEMATOLOGICA

RNAi-mediated CCR5 Silencing by LFA-1-targeted Nanoparticles Prevents HIV Infection in BLT Mice

(2009) Sang-Soo Kim et al.   MOLECULAR THERAPY

Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2

(2008) M Klier et al.   LEUKEMIA

Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target

(2008) D. Peer et al.   SCIENCE